Tessella Inc. Report issue

For profit Phase 3
Founded: Abingdon United Kingdom (1979)
Status: No NME R&D (1979)

Organization Overview

First Clinical Trial
2008
NCT00734474
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

dulaglutide (trulicity) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2